A5010074107- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Hepatitis C virus research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver physiology and pathology
- Liver Disease and Transplantation
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Genetic factors in colorectal cancer
- RNA modifications and cancer
- Microtubule and mitosis dynamics
- Organ Transplantation Techniques and Outcomes
- Cutaneous Melanoma Detection and Management
- Diet, Metabolism, and Disease
- Cancer Treatment and Pharmacology
- Autophagy in Disease and Therapy
- Cancer Mechanisms and Therapy
- Melanoma and MAPK Pathways
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2016-2024
Universitat de Barcelona
2015-2024
Hospital Clínic de Barcelona
2015-2024
Hospital Universitari de Vic
2024
Icahn School of Medicine at Mount Sinai
2019-2023
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2016-2019
Cornell University
2017
SUNY Upstate Medical University
2017
University at Buffalo, State University of New York
2017
Hospital Del Mar
2017
Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification patients optimal response to therapy unmet need 6,7 Here we report the progressive accumulation exhausted, unconventionally activated CD8 + PD1 T cells in NASH-affected livers. In preclinical models NASH-induced therapeutic immunotherapy targeted at programmed...
We previously reported a characterisation of the hepatocellular carcinoma (HCC) immune contexture and described an immune-specific class. now aim to further delineate immunogenomic classification HCC incorporate features that explain responses/resistance immunotherapy.
Background and Aims Lenvatinib is an effective drug in advanced HCC. Its combination with the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results phase Ib currently being tested III trials. Here, we aimed to explore molecular immunomodulatory effects of lenvatinib alone or anti‐PD1. Approach Results We three syngeneic models HCC C57BL/6J mice (subcutaneous orthotopic) randomized animals receive placebo, lenvatinib,...
Sustained virological response (SVR) improves survival in post-liver transplant (LT) recurrent hepatitis C. However, the impact of SVR on fibrosis regression is not well defined. In addition, performance noninvasive methods to evaluate presence and portal hypertension (PH) post-SVR has been scarcely evaluated. We aimed investigate degree (decrease ≥1 METAVIR stage) after-SVR its associated factors C, as diagnostic capacity assessment liver PH after viral clearance. evaluated 112 C...
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding the mechanisms AFP overexpression and molecular traits AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data DNA methylome profiling 520 HCC from two independent cohorts to identify distinct (serum concentration > 400 ng/ml), which represents an accepted prognostic cut-off predictor response...
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity pandemic but at present there are no approved therapies. Here, we aimed revert high-fat diet (HFD)-induced and NAFLD in mice by enhancing acid oxidation (FAO). Moreover, searched for potential new lipid biomarkers monitoring steatosis humans. We used adeno-associated virus (AAV) deliver a permanently active mutant form human carnitine palmitoyltransferase 1A (hCPT1AM), key enzyme...
Abstract Purpose: Immune checkpoint inhibitors combined with antiangiogenic agents produce benefits in the treatment of advanced hepatocellular carcinoma (HCC). We investigated efficacy and immunomodulatory activity cabozantinib alone anti-PD1 experimental models HCC, explored potential target population that might benefit from this combination. Experimental Design: C57BL/6J mice bearing subcutaneous Hepa1-6 or Hep53.4 tumors received cabozantinib, anti-PD1, their combination, placebo. Tumor...
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance common and constitutes main reason failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results largely deceiving. We analysed time to progression, overall survival, mutational status of RAS, BRAF nuclear p-IGF-1R expression by immunohistochemistry, 470 CRC patients. The effect...
: The accumulation of adipose tissue macrophages (ATMs) in obesity has been associated with hepatic injury. However, the contribution ATMs to fibrosis non-alcoholic fatty liver disease (NAFLD) remains be elucidated. Herein, we investigate relationship between and patients NAFLD evaluate impact modulation over an experimental steatohepatitis (NASH) model.Adipose biopsies from 42 different stages were collected. characterised by immunohistochemistry flow cytometry correlation was assessed....
Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB assess efficacy molecular therapies preclinical models HB. Paired tumor adjacent tissues from 31 HBs a validation set 50 were analyzed using RNA-seq, SNP, methylation arrays. IGF2 overexpression was identified as top targetable driver, present 71% (22/31). IGF2high tumors displayed...
Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR)α and β/δ agonist that has reached phase III clinical trial for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we examined effects elafibranor in mice fed choline-deficient high-fat diet (CD-HFD), model steatohepatitis (MASH) presents obesity insulin resistance. Our findings revealed ameliorated steatosis, inflammation, fibrogenesis livers CD-HFD-fed mice. Unexpectedly, also...
Pathologic lymph node staging is becoming a deficient method in the demanding molecular era. Nevertheless, use of more sensitive analysis for nodal hampered by its high costs and extensive time requirements. Our aim to take step forward colon cancer (CC) (LN) pathology diagnosis proposing feasible efficient routine practice using reverse transcription loop-mediated isothermal amplification (RT-LAMP). Molecular detection tumor cytokeratin 19 (CK19) mRNA with RT-LAMP was performed 3206 LNs...
Colorectal cancer (CRC) screening programs result in the detection of early-stage asymptomatic carcinomas suitable to be surgically cured. Lymph nodes (LN) from early CRC are usually small and may difficult collect. Still, at least 12 LNs should analyzed colectomies, ensure a reliable pN0 stage. Presurgical endoscopic tattooing improves LN procurement. In addition, molecular occult tumor burden histologically patients is associated with decreased survival rate. We aimed study impact...
Abstract Purpose: Mongolia has the world's highest incidence of hepatocellular carcinoma (HCC), with ∼100 cases/100,000 inhabitants, although reasons for this have not been thoroughly delineated. Experimental Design: We performed a molecular characterization Mongolian (n = 192) compared Western 187) HCCs by RNA sequencing and whole-exome to unveil distinct genomic transcriptomic features associated environmental factors in population. Results: patients were younger, higher female prevalence,...
Aims The current WHO classification of melanocytic tumours excludes neoplasms showing BRAF or NRAS mutations from the Spitz category. This study aimed to review and reclassify atypical with spitzoid morphological features diagnosed between 2009 2021 in our hospital after expanding molecular profile, including all cases. Methods results A total 71 (Spitz‐like) atypia were included. risk progression was first studied by integrating morphology, immunohistochemistry (p16, Ki67, HMB45 PRAME)...